1. Home
  2. KURA vs PWP Comparison

KURA vs PWP Comparison

Compare KURA & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • PWP
  • Stock Information
  • Founded
  • KURA 2014
  • PWP 2006
  • Country
  • KURA United States
  • PWP United States
  • Employees
  • KURA N/A
  • PWP N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • PWP Finance: Consumer Services
  • Sector
  • KURA Health Care
  • PWP Finance
  • Exchange
  • KURA Nasdaq
  • PWP Nasdaq
  • Market Cap
  • KURA 1.3B
  • PWP 1.4B
  • IPO Year
  • KURA N/A
  • PWP N/A
  • Fundamental
  • Price
  • KURA $15.92
  • PWP $25.25
  • Analyst Decision
  • KURA Strong Buy
  • PWP Hold
  • Analyst Count
  • KURA 7
  • PWP 3
  • Target Price
  • KURA $29.83
  • PWP $18.83
  • AVG Volume (30 Days)
  • KURA 821.5K
  • PWP 510.6K
  • Earning Date
  • KURA 11-07-2024
  • PWP 11-08-2024
  • Dividend Yield
  • KURA N/A
  • PWP 1.11%
  • EPS Growth
  • KURA N/A
  • PWP N/A
  • EPS
  • KURA N/A
  • PWP N/A
  • Revenue
  • KURA N/A
  • PWP $864,769,000.00
  • Revenue This Year
  • KURA N/A
  • PWP $27.82
  • Revenue Next Year
  • KURA N/A
  • PWP $15.58
  • P/E Ratio
  • KURA N/A
  • PWP N/A
  • Revenue Growth
  • KURA N/A
  • PWP 39.74
  • 52 Week Low
  • KURA $9.06
  • PWP $10.73
  • 52 Week High
  • KURA $24.17
  • PWP $25.96
  • Technical
  • Relative Strength Index (RSI)
  • KURA 34.68
  • PWP 66.83
  • Support Level
  • KURA $16.55
  • PWP $23.34
  • Resistance Level
  • KURA $19.73
  • PWP $25.96
  • Average True Range (ATR)
  • KURA 0.98
  • PWP 1.06
  • MACD
  • KURA -0.05
  • PWP 0.34
  • Stochastic Oscillator
  • KURA 8.86
  • PWP 88.42

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

Share on Social Networks: